股份發行人及根據《上市規則》第十九B章上市的香港預託證券發行人的證券變動月報表 | 截至月份: | 2025年7月31日 | 狀態: | 新提交 | | --- | --- | --- | --- | | 致：香港交易及結算所有限公司 | | | | | 公司名稱: | 云康集团有限公司 | | | | 呈交日期: | 2025年8月4日 | | | | I. 法定/註冊股本變動 | | | | | 1. 股份分類 | 普通股 | 股份類別 | 不適用 | | | 於香港聯交所上市 (註1) | | 是 | | | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | | 證券代號 (如上市) | 02325 | 說明 | 普通股 | | | | | | | | | | 法定/註冊股份數目 | | | 面值 | | | 法定/註冊股本 | | | 上月底結存 | | | 25,000,000,000 | USD | | 0.000002 | USD | | 50,000 | | 增加 / 減少 (-) | | | | | | | USD | | ...

张为结先生已获委任为公司非执行董事，自2025年8月1日起生效。 云康集团(02325)发布公告，黄珞女士为投入更多时间处理其个人事务而辞任公司非执行董事，自2025 年8月1日起生效。 ...

格隆汇8月1日丨云康集团(02325.HK)发布公告，黄珞为投入更多时间处理其个人事务而辞任公司非执行 董事，自2025年8月1日起生效。张为结已获委任为公司非执行董事，自2025年8月1日起生效。 ...

张为结先生已获委任为公司非执行董事，自2025年8月1日起生效。 智通财经APP讯，云康集团(02325)发布公告，黄珞女士为投入更多时间处理其个人事务而辞任公司非执 行董事，自2025年8月1日起生效。 ...

中國廣州 2025年8月1日 云康集团有限公司董事會（「董事會」）成員載列如下： 張勇先生 （董事長、執行董事） 張為結先生 （非執行董事） 王憑慧博士 （非執行董事） 王瑞華博士 （非執行董事） 喻世友先生 （獨立非執行董事） 謝少華先生 （獨立非執行董事） 董敏博士 （獨立非執行董事） 董事會下設三個委員會。下表提供各董事會成員在該等委員會中所擔任的職位。 | | 委員會 | | | | | --- | --- | --- | --- | --- | | 董事 | | 審核委員會 | 薪酬委員會 | 提名委員會 | | 張勇先生 | | | 成員 | 主席 | | 張為結先生 | | | | | | 王憑慧博士 | | | | | | 王瑞華博士 | | 成員 | | | | 喻世友先生 | | 成員 | 主席 | | | 謝少華先生 | | 主席 | 成員 | 成員 | | 董敏博士 | | | | 成員 | Yunkang Group Limited 云康集团有限公司 （於開曼群島註冊成立的有限公司） （股份代號：2325） 董事名單與其角色及職能 ...

香港交易及結算所有限公司及香港聯合交易所有限公司對本公告的內容概不負責，對其準確性 或完整性亦不發表任何聲明，並明確表示概不就因本公告全部或任何部分內容所產生或因依賴 該等內容而引致的任何損失承擔任何責任。 YUNKANG GROUP LIMITED 云康集团有限公司 （於開曼群島註冊成立的有限公司） 非執行董事辭任 董事（「董事」）會（「董事會」）欣然宣佈，黃珞女士（「黃女士」）為投入更多時間處 理其個人事務而辭任本公司非執行董事，自2025年8月1日起生效。黃女士已確 認，彼與董事會並無意見分歧，且概無有關彼辭任之事宜須提請本公司股東及聯 交所垂注。董事會謹藉此機會對黃女士於任期內為本集團作出之貢獻表示感謝。 委任非執行董事 董事會欣然宣佈，張為結先生（「張先生」）已獲委任為本公司非執行董事，自2025 年8月1日起生效。 1 有關張先生之資料 張先生之履歷詳情載列如下： （股份代號：2325） 非執行董事變更 本公告乃由云康集团有限公司（「本公司」，連同其附屬公司及綜合聯屬實體統稱 「本集團」）根據香港聯合交易所有限公司（「聯交所」）證券上市規則（「上市規則」） 第13.51(2)條而作出。 張先生已與 ...

Core Viewpoint - The third-party medical testing industry in China has experienced significant growth, particularly during the pandemic, with a market size reaching 630.5 billion yuan in 2022, but is expected to return to pre-pandemic levels in 2023 and stabilize around 388.8 billion yuan in 2024 [1][6]. Group 1: Industry Definition and Business Model - Medical testing is a discipline that utilizes modern physical and chemical methods for clinical diagnosis and treatment [2]. - Independent clinical laboratories (ICLs), also known as third-party medical laboratories, operate independently of hospitals and are licensed by health authorities to provide clinical testing and pathology services [2]. Group 2: Current Development Status - The ICL industry in China began in the 1980s and has become an essential part of the healthcare system due to increasing demand and favorable policies [4]. - The number of ICLs has grown from fewer than 70 in 2009 to an estimated 2,800 by 2024, with projections of reaching 2,845 by 2025 [4]. Group 3: Market Size and Growth Projections - The market size for third-party medical testing services in China was 630.5 billion yuan in 2022, with a significant drop expected in 2023 as pandemic testing demands decrease [6]. - The projected market size for 2024 is 388.8 billion yuan, with special testing accounting for 189.3 billion yuan and general testing for 199.5 billion yuan [6]. - By 2025, the market is expected to grow to approximately 444.9 billion yuan, with special testing at 218.1 billion yuan and general testing at 226.8 billion yuan [6]. Group 4: Industry Chain Structure - The third-party medical testing industry relies on specialized medical services, acting as a substitute for traditional hospital testing departments [8]. - The upstream of the industry includes suppliers of medical devices and testing reagents, while the downstream consists of various healthcare institutions that increasingly outsource testing services [8]. Group 5: Competitive Landscape - The market is characterized by a concentration of major players, with KingMed and Dian Diagnostics holding a combined market share of 36.16% [15]. - KingMed leads the market with a 17.04% share, providing services to over 20,000 medical institutions across 31 provinces and regions [15]. - Smaller third-party testing institutions face challenges due to limited scale and capabilities, leading to market exit pressures since 2015 [15]. Group 6: Financial Performance of Key Players - In 2024, KingMed reported revenues of 6.627 billion yuan, Dian Diagnostics 4.520 billion yuan, and Aidi Kang 2.914 billion yuan, among others [18]. Group 7: Development Trends - The third-party medical testing sector is becoming increasingly important, with regulatory changes posing new challenges [20]. - The industry is expected to focus on technological upgrades and strategic partnerships to enhance profitability and service quality [20]. - Automation, platformization, and intelligence are emerging as key trends in the development of third-party medical laboratories [20].

Group 1 - The biotechnology stocks in the Hong Kong market mostly declined, with notable drops in several companies [1] - Kangfang Biotech (09926.HK) experienced a decline of over 12% [1] - Yunkang Group (02325.HK) fell by more than 6% [1] - Other companies such as Sillod Medical (01244.HK) and Zai Lab (09688.HK) also saw declines exceeding 4% [1]

Financial Performance - The company reported a comprehensive income statement for the fiscal year ending December 31, 2024, detailing financial performance metrics [3]. - The five-year financial summary indicates a consistent growth trend, with significant increases in revenue and net income compared to previous years [5]. - The company reported revenue of RMB 711.9 million for the year ended December 31, 2024, a decrease of 20.1% compared to RMB 891.5 million in 2023 [19]. - The net loss for the company was RMB 793.2 million, significantly higher than the net loss of RMB 101.9 million recorded in 2023, representing an increase of 678.4% [19]. - The gross profit decreased by 35.2% to RMB 211.1 million, down from RMB 325.8 million in the previous year [18]. - The company's diagnostic testing services recorded revenue of RMB 711.9 million, a decrease of 20.1% compared to the same period last year [40]. - Revenue from diagnostic testing services provided to medical alliances decreased by 12.4% to RMB 377.3 million, accounting for 53.0% of total revenue, an increase of 4.7% year-on-year [56]. - Revenue from diagnostic outsourcing services fell by 27.0% to RMB 301.8 million, primarily due to increased industry competition and a slowdown in market demand [57]. - Revenue from diagnostic testing services for non-medical institutions decreased by 30.3% to RMB 32.8 million, impacted by external market conditions [58]. - The company's gross profit margin for the year ended December 31, 2024, was 29.6%, down from 36.5% in 2023 [87]. Strategic Initiatives - Future outlook suggests a projected revenue growth of 20% for the next fiscal year, driven by new product launches and market expansion initiatives [5]. - The company is investing in R&D for new technologies, with a budget allocation of $10 million aimed at enhancing product offerings [5]. - Market expansion plans include entering three new international markets by the end of 2025, targeting a 25% increase in global market share [5]. - The company is considering strategic acquisitions to bolster its market position, with potential targets identified in the healthcare sector [5]. - A new product line is set to launch in Q2 2025, expected to contribute an additional $5 million in revenue within the first year [5]. - The company aims to build a dual innovation-driven system with a "Six Forces Model + AI Model" to support the full chain transition from laboratory to industrialization [27]. - The company implemented a "horizontal and vertical" strategy to enhance the medical service ecosystem, focusing on regional medical testing centers and establishing joint laboratories with leading enterprises [29]. Operational Efficiency - The company reported a 30% increase in operational efficiency due to recent technological upgrades and process optimizations [5]. - The company is committed to enhancing credit control and collection efforts for clients with good credit ratings to manage accounts receivable levels [20]. - The company focused on optimizing its client and product structure, which contributed to a decline in overall diagnostic testing service revenue [20]. - The company has successfully introduced several AI-assisted diagnostic applications, enhancing diagnostic efficiency and effectiveness [52]. - AI technology has been fully integrated into the group's medical laboratories, significantly improving testing efficiency and report turnaround time [51]. Research and Development - Research and development expenses were approximately RMB 53.0 million, increasing the R&D expenditure as a percentage of total revenue from 6.2% in 2023 to 7.4% in 2024 [20]. - The company initiated 11 research collaborations with 9 leading hospitals in 4 provinces, leading to 4 projects with promotable results in the field of infectious disease diagnostics [23]. - The "Medical Testing Joint Innovation Platform" has successfully developed over 10 different diagnostic products for various infectious syndromes in collaboration with top medical institutions [44]. Corporate Governance - The company has adopted corporate governance codes and principles to ensure high standards of governance and shareholder protection [130]. - The board consists of one executive director, three non-executive directors, and three independent non-executive directors [134]. - The company has established three committees: audit committee, remuneration committee, and nomination committee, to oversee various aspects of its operations [150]. - The company emphasizes integrity and accountability as core values to drive employee potential and sustainable development [127]. - The company has a strong commitment to corporate governance, believing it is essential for enhancing company value and accountability [129]. Challenges and Risks - The company may face adverse impacts on its business, financial condition, and prospects if it cannot raise sufficient additional funds under acceptable terms [200]. - Uncertainties related to China's bulk purchasing policies may affect the company's operations [200]. - Failure to keep pace with industry and technological developments in a cost-effective manner may hinder the company's competitiveness and reduce demand for its services [200]. - The business may be adversely affected by obstacles in China's healthcare reform [200]. - Inability to effectively recover trade receivables could negatively impact the company's business, financial condition, and operating performance [200].

Financial Performance - The company reported revenue of RMB 711.9 million for the year ended December 31, 2024, a decrease of 20.1% compared to RMB 891.5 million in 2023[7]. - The net loss for the year was RMB 793.2 million, significantly widening from a net loss of RMB 101.9 million in the previous year, representing an increase of 678.4%[7]. - Gross profit decreased by 35.2% to RMB 211.1 million, down from RMB 325.8 million in 2023[4]. - Basic and diluted loss per share increased to RMB (1.33) from RMB (0.17), reflecting a 682.4% increase[6]. - The company reported a loss attributable to owners of RMB 791,682,000 for the year ended December 31, 2024, compared to a loss of RMB 102,259,000 in 2023, representing a significant increase in losses[31]. - The loss before tax increased significantly from RMB 86.8 million for the year ending December 31, 2023, to RMB 791.2 million for the year ending December 31, 2024, attributed to lower-than-expected growth in routine testing demand and high fixed costs[82]. Revenue Breakdown - Total revenue from diagnostic services for the year ended December 31, 2024, was RMB 711,884,000, a decrease of 20.2% from RMB 891,500,000 in 2023[19]. - Revenue from the southern region of China was RMB 565,055,000, down 22.8% from RMB 732,061,000 in 2023[21]. - Revenue from diagnostic testing services provided to medical alliances decreased by 12.4% to RMB 377.3 million, accounting for 53.0% of total revenue, an increase of 4.7% year-on-year[69]. - Revenue from diagnostic outsourcing services fell by 27.0% to RMB 301.8 million, primarily due to increased industry competition and a slowdown in market demand[70]. - Revenue from diagnostic testing services for non-medical institutions decreased by 30.3% to RMB 32.8 million, impacted by external market conditions[71]. Expenses and Losses - The company recorded a significant increase in credit impairment losses, amounting to RMB 536.2 million, compared to RMB 104.6 million in the previous year[8]. - Selling expenses increased by 19.5% to RMB 180.2 million, driven by higher sales staff and operational service costs[75]. - Administrative expenses rose by 38.2% to RMB 264.8 million, influenced by measures to expedite trade receivables recovery and one-time consulting service costs[75]. - Financial asset impairment losses increased by 412.6% from RMB 104.6 million for the year ending December 31, 2023, to RMB 536.2 million for the year ending December 31, 2024, primarily due to provisions for trade receivables[79]. Assets and Liabilities - Total assets decreased to RMB 3,228.3 million from RMB 4,532.1 million in 2023[11]. - Total liabilities decreased to RMB 2,078,459,000 in 2024 from RMB 2,412,195,000 in 2023, reflecting a reduction of 13.8%[22]. - Total equity as of December 31, 2024, was RMB 1,149,877,000, down from RMB 2,119,857,000 in 2023, representing a decrease of 45.8%[22]. - Current liabilities decreased to RMB 1,916,435,000 in 2024 from RMB 2,188,631,000 in 2023, a decline of 12.4%[22]. - Trade receivables significantly declined to RMB 628.5 million from RMB 1,515.5 million in the previous year[11]. Research and Development - Research and development expenses rose to RMB 53.0 million, accounting for 7.4% of total revenue, up from 6.2% in 2023[8]. - R&D expenses decreased by 4.2% from RMB 55.3 million for the year ending December 31, 2023, to RMB 53.0 million for the year ending December 31, 2024, while the proportion of R&D expenses to total revenue increased from 6.2% to 7.4%[77]. Strategic Initiatives - The company is focusing on optimizing customer and product structures to enhance operational efficiency amid increased industry competition[8]. - The management plans to strengthen credit control and collection efforts to mitigate the impact of extended payment cycles from certain customers[8]. - The company is actively involved in the healthcare sector, which is expected to drive economic growth, supported by government policies and technological innovations[46]. - The company is focusing on innovative service models based on specialization, standardization, and digitalization to empower healthcare development[53]. Market and Industry Trends - The integration of AI technology in medical testing is enhancing diagnostic accuracy and efficiency, reducing costs, and accelerating innovation[50]. - The national health policy aims for over 90% of counties to establish a tight-knit medical community by the end of 2025, promoting the construction of a hierarchical medical system[48]. - The company anticipates that advancements in AI and international cooperation will enhance the healthcare sector's development and resource sharing[46]. Employee and Corporate Governance - The total salary cost for the year ending December 31, 2024, was RMB 299.8 million, slightly up from RMB 299.7 million for the previous year[110]. - The company had 1,249 employees as of December 31, 2024, down from 1,510 employees as of December 31, 2023[110]. - The board of directors does not recommend the distribution of a final dividend for the year ending December 31, 2024[120].